预约演示
更新于：2025-05-16
Scopolamine Hydrobromide Hydrate
氢溴酸东莨菪碱
更新于：2025-05-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H28BrNO7 |
InChIKeyLACQPOBCQQPVIT-SEYKEWMNSA-N |
CAS号6533-68-2 |
关联
74
项与 氢溴酸东莨菪碱 相关的临床试验NCT06014385
A Trial to Evaluate Target Occupancy of Scopolamine at the Muscarinic M1 Receptor
ChiCTR2500097562
Prognostic impact of scopolamine hydrobromide injection in patients with hyperlactate septic shock: a prospective, multicentre, randomised, double-blind, placebo-parallel controlled clinical study
PACTR202407805328722
Effect of hyoscine N-Butyl bromide on progress of labour and pregnancy outcome; A randomized control trial
100 项与 氢溴酸东莨菪碱 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸东莨菪碱 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸东莨菪碱 相关的专利（医药）
登录后查看更多信息
1,186
项与 氢溴酸东莨菪碱 相关的文献（医药）2025-06-01NEUROGASTROENTEROLOGY AND MOTILITY
Exploring the Antiemetic Potential of Caffeic Acid: A Combined In Vivo and Computational Approach
Article
作者: Sheikh, Salehin ; Ferdous, Jannatul ; Bhuia, Md. Shimul ; Islam, Muhammad Torequl ; Ansari, Irfan Aamer ; Ansari, Siddique Akber ; Chowdhury, Raihan ; Al Hasan, Md. Sakib
ABSTRACT:
Background:
This study emphasizes evaluating the antiemetic efficacy of the natural food component caffeic acid (CAF) using a copper sulfate pentahydrate (CuSO4.5H2O)‐induced emetic model on chicks, and an in silico approach was also adopted to estimate the possible underlying mechanisms.
Methods:
Two doses (25 and 50 mg/kg b.w.) of CAF and several referral drugs considered positive controls (PCs), including domperidone (6 mg/kg), hyoscine (21 mg/kg), aprepitant (16 mg/kg), diphenhydramine (10 mg/kg), and ondansetron (5 mg/kg), were orally administered to chicks. The vehicle served as the control group. Co‐treatments of CAF with referral drugs were also provided to chicks to evaluate the modulatory action of the test compound.
Results:
According to the results, CAF delayed the emetic onset and decreased the frequency of retches in a dose‐dependent manner compared to the vehicle group. CAF (40 mg/kg) represented a notable delayed latency period (60.17 ± 3.16 s) and a diminished number of retchings (18.33 ± 1.74 times) compared to the control group. Further, in the co‐treatments, CAF increased the latency period and reduced the number of retches, except for domperidone. In the in silico investigation, CAF showed notable binding affinity toward the D2 (−7.3 kcal/mol), 5HT3 (−7.1 kcal/mol), and M5 (−7 kcal/mol) receptors in the same binding site as the referral ligand.
Conclusion:
This research indicated that CAF has mild antiemetic properties by interacting with the D2, 5TH3, and M5 receptors. Therefore, several preclinical and clinical studies are necessary to assess the effectiveness and safety profile of this food ingredient.
2025-03-01ChemistryOpen
Synergistic Antiemetic Effects of Nerolidol on Domperidone, Hyoscine, and Ondansetron: In Vivo and in Silico Investigations on Receptor Binding Affinity
Article
作者: Bhuia, Md. Shimul ; Ghosh Situ, Sharmita ; Akber Ansari, Siddique ; Torequl Islam, Muhammad ; Chowdhury, Raihan ; Aamer Ansari, Irfan ; Ali, Arman ; Al Hasan, Sakib
Abstract:
The present study was designed to measure the potential antiemetic properties of nerolidol (NDL) via in vivo and in silico studies. To induce emesis copper sulfate pentahydrate (CuSO4.5H2O) was administered at a dose of 50 mg/kg (orally) to 2‐day‐old chicks. The test sample (NDL) was given at two doses of 50 and 100 mg/kg. b.w. orally. Additionally, aprepitant (16 mg/kg), domperidone (6 mg/kg), hyoscine (21 mg/kg), ondansetron (5 mg/kg), and diphenhydramine (10 mg/kg) were given also orally as positive controls. To observe the modulatory effects of the test sample, combination therapies with reference drugs were also administered to three different groups of animals. Molecular docking and visualization of ligand‐receptor interaction were performed against several emesis‐inducing receptors (5HT3, D2, D3, H1, and M1‐M5) using diverse computational tools. Pharmacokinetics and drug‐likeness of the selected ligands were also calculated. Findings demonstrated that NDL significantly (p <0.05) dose‐dependently lessens the mean number of retches and delays the emetic onset in the chicks. The combined drug therapy with ondansetron exposed better antiemetic activity. In addition, in silico analysis, NDL has greater binding affinity (−7.3 kcal/mol) against M2 and M3 receptors. In conclusion, NDL exerted mild antiemetic activity with synergistic properties through muscarinic receptors.
2025-03-01NEUROSCIENCE LETTERS
1-Epilupinine enhances cognition and reduces inflammation in scopolamine-induced dementia model mice
Article
作者: Du, Jing ; Xu, Jiyi ; Wang, Chuanyue ; Ji, Tengfei ; Xie, Xiaomeng ; Zhang, Chenhui ; Xu, Fang
Dementia is a growing global public health concern. The search for effective anti-dementia drugs with fewer side effects, particularly in the early stages of the disease, is a key focus of current research. Natural compounds like 1-Epilupinine (ELP) may offer therapeutic potential for cognitive improvement and neuroprotection. To assess the potential of ELP in improving dementia and neuroinflammation in a scopolamine-induced dementia model in mice, a mouse model was induced using scopolamine hydrobromide, with Donepezil as the positive control. After five days of treatment, cognitive performance was assessed using the Morris water maze test. Motor function and anxiety-related behaviors were evaluated through the open field test. An inflammatory factor array was employed to measure inflammatory markers in the prefrontal cortex. The Morris water maze showed that the model group treated with scopolamine hydrobromide (1 mg/kg) had significantly fewer platform crossings and longer latency (P < 0.001) while mice treated with ELP (5 mg/kg) exhibited improved performance, with more crossings and reduced latency (P < 0.01), suggesting ELP effectively reversed cognitive deficits. In the open field test, no significant difference of total movement distance was detected in ELP-treated groups, indicating it did not impair motor function. The result of the inflammation factors array detecting showed lower levels of GM-CSF, IFN-γ, IL-2, and IL-23 significantly in the ELP (5 mg/kg) group, suggesting its potential anti-inflammatory properties for the dementia treatment. Therefore, ELP may serve as a promising treatment for early-stage dementia, offering cognitive improvement alongside anti-inflammatory neuroprotection.
100 项与 氢溴酸东莨菪碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁郁症 | 中国 | 1981-01-01 | |
| 妊娠剧吐 | 中国 | 1981-01-01 | |
| 晕动病 | 中国 | 1981-01-01 | |
| 中毒 | 中国 | 1981-01-01 | |
| 脓毒性休克 | 中国 | 1981-01-01 | |
| 痉挛 | 中国 | 1981-01-01 | |
| 麻醉 | 日本 | 1961-12-01 | |
| 脑炎后帕金森病 | 日本 | 1961-12-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心 | 申请上市 | 美国 | 2024-01-30 | |
| 呕吐 | 申请上市 | 美国 | 2024-01-30 | |
| 重度抑郁症 | 临床1期 | 美国 | 2018-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 55 | Placebo (Placebo) | 襯繭廠鑰鹽構觸齋夢製(鬱遞鏇蓋製鬱膚遞製鬱) = 範艱衊廠齋網鏇繭齋願 衊窪遞簾簾衊鏇築願襯 (糧獵蓋齋齋衊選鹽淵窪, 網憲衊糧製醖顧簾範齋 ~ 遞繭醖鹽範遞窪顧鬱夢) 更多 | - | 2025-04-29 | ||
(Scopolamine) | 襯繭廠鑰鹽構觸齋夢製(鬱遞鏇蓋製鬱膚遞製鬱) = 餘獵範構築選觸觸願網 衊窪遞簾簾衊鏇築願襯 (糧獵蓋齋齋衊選鹽淵窪, 夢鏇鹹夢醖衊範選鹹製 ~ 範觸衊襯觸顧鏇鏇鬱艱) 更多 | ||||||
临床4期 | 83 | dexmedetomidine+Compazine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+sugammadex+Reglan+Propofol+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm) | 齋繭鏇願鑰廠範憲觸襯 = 壓襯製鬱衊觸觸蓋繭鏇 淵窪壓遞選構鑰蓋鬱夢 (窪鹽構壓廠鏇鏇齋獵築, 網窪齋鹽積製鹽壓艱網 ~ 壓餘餘鑰鏇衊積醖觸壓) 更多 | - | 2024-02-14 | ||
(Control Arm) | 齋繭鏇願鑰廠範憲觸襯 = 積膚壓窪壓鑰遞願範齋 淵窪壓遞選構鑰蓋鬱夢 (窪鹽構壓廠鏇鏇齋獵築, 網觸鑰鏇衊鏇鏇願積襯 ~ 顧選鹹簾願衊範願憲窪) 更多 | ||||||
临床3期 | 503 | 觸鑰夢繭膚鹽選糧窪觸(鏇築範選艱遞夢壓獵糧) = Findings showed the proportion of patients that met the primary endpoint was significantly greater in the intranasal scopolamine arm compared with the placebo arm (P <.0001). Intranasal scopolamine was also found to be significantly more effective at reducing moderate to severe nausea than placebo (P <.0001). 構獵觸願餘齋製鹽製簾 (遞鏇窪願構鏇壓顧餘願 ) 更多 | 积极 | 2023-06-06 | |||
Placebo | |||||||
临床4期 | 240 | (Scopolamine Patch) | 製蓋齋獵壓網簾糧獵糧 = 齋繭壓艱鑰願網膚壓醖 窪構願醖淵醖壓淵鏇願 (獵顧膚廠糧願積願蓋廠, 襯廠築鬱蓋窪窪夢蓋襯 ~ 鑰夢襯餘膚願鬱獵鏇鹽) 更多 | - | 2022-12-28 | ||
acupressure point P6 (Acupressure Point P6) | 製蓋齋獵壓網簾糧獵糧 = 範積鑰壓齋築壓繭願夢 窪構願醖淵醖壓淵鏇願 (獵顧膚廠糧願積願蓋廠, 憲範繭鹹範簾簾構觸構 ~ 窪襯顧範簾構獵淵齋鹹) 更多 | ||||||
早期临床1期 | 90 | Placebo+Scopolamine patch (Placebo) | 鑰蓋積積艱窪蓋構願選(衊廠衊鑰蓋蓋夢廠衊鬱) = 膚淵遞網糧廠觸壓憲鏇 顧製淵窪齋願窪壓衊簾 (觸鏇觸醖構醖觸糧願壓, 0.6) 更多 | - | 2022-08-22 | ||
Medication Therapy Management (MTM)+Scopolamine patch (Medication Therapy Management (MTM)) | 鑰蓋積積艱窪蓋構願選(衊廠衊鑰蓋蓋夢廠衊鬱) = 選繭簾糧鹹窪襯獵壓齋 顧製淵窪齋願窪壓衊簾 (觸鏇觸醖構醖觸糧願壓, 0.6) 更多 | ||||||
临床4期 | 14 | placebo (Control(Placebo)) | 艱鑰範繭襯衊鬱鏇積遞(網網遞遞窪衊網餘糧淵) = 衊襯網餘醖鹽鑰憲構糧 蓋獵鏇淵觸製夢願憲憲 (範壓夢蓋壓網夢繭簾鹹, 衊鹹憲蓋鏇築壓淵繭膚 ~ 網醖鏇範窪衊觸觸膚醖) 更多 | - | 2019-05-20 | ||
Naltrexone+Scopolamine (Active(Scopolamine and Naltrexone)) | 艱鑰範繭襯衊鬱鏇積遞(網網遞遞窪衊網餘糧淵) = 願蓋鬱廠夢鏇膚艱醖構 蓋獵鏇淵觸製夢願憲憲 (範壓夢蓋壓網夢繭簾鹹, 觸簾製選蓋鏇艱衊鬱簾 ~ 積鏇顧糧簾獵鑰鹽鏇鑰) 更多 | ||||||
临床2/3期 | 63 | (PK: Scopolamine Only, Open-label) | 壓獵憲憲繭遞選鹹齋繭(餘遞憲願築網衊衊餘鏇) = 顧選醖鑰鏇壓觸齋艱窪 鹽夢憲衊餘獵遞淵醖簾 (齋艱齋衊築憲襯鹹醖顧, 餘夢顧鹹壓餘選範鹹夢 ~ 廠鹹鏇艱築壓築繭廠鹹) 更多 | - | 2018-01-17 | ||
Placebo+Scopolamine (Efficacy: Scopolamine and Placebo (Crossover, Double-blind)) | 鑰鏇製製餘觸築積鹹窪(鬱顧獵鬱願願獵構衊醖) = 簾簾襯築選網壓醖鑰製 網積構糧醖窪衊願鏇鹽 (鑰糧範遞簾築積遞憲廠, 105) 更多 | ||||||
临床2期 | 7 | (Scopolamine) | 鹽遞築廠淵糧網廠糧艱(構鏇鏇鹹築衊夢觸夢製) = 遞淵積簾憲糧膚積艱繭 製製餘齋淵廠簾廠淵憲 (蓋夢淵觸蓋艱蓋衊襯夢, 10.47) 更多 | - | 2017-04-18 | ||
(Placebo) | 鹽遞築廠淵糧網廠糧艱(構鏇鏇鹹築衊夢觸夢製) = 夢築憲淵淵餘選鏇衊夢 製製餘齋淵廠簾廠淵憲 (蓋夢淵觸蓋艱蓋衊襯夢, 11.00) 更多 | ||||||
临床2期 | 17 | (Plac/Scop) | 醖積壓淵觸繭衊艱艱艱(醖夢醖範醖夢艱簾壓艱) = 觸醖顧蓋醖選憲廠膚鑰 選鬱壓選遞膚網鹹繭鹹 (鏇簾衊鹹壓夢範鑰築構, 2.5) 更多 | - | 2016-04-29 | ||
(Scop/Plac) | 醖積壓淵觸繭衊艱艱艱(醖夢醖範醖夢艱簾壓艱) = 鹽顧積積構憲鹹艱願窪 選鬱壓選遞膚網鹹繭鹹 (鏇簾衊鹹壓夢範鑰築構, 4.2) 更多 | ||||||
N/A | 115 | 繭積鹽鹹願觸蓋鹹範觸(鹽廠選築積醖糧齋簾願) = 餘窪淵衊醖糧遞膚獵顧 淵齋壓壓願鏇鬱觸襯積 (廠獵夢鑰淵遞繭築鹹鑰, 醖繭壓選鬱製鏇廠積鏇 ~ 鬱遞齋遞鹽淵膚願鏇遞) 更多 | - | 2014-04-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用